Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More

BackgroundThis study aimed to analyze the economics of pembrolizumab plus chemotherapy as first-line treatment in patients with esophageal squamous cell carcinoma (ESCC) and programmed cell death-Ligand 1 (PD-L1) combined positive score (CPS) of 10 or more in China.MethodsBased on the advanced ESCC...

Full description

Bibliographic Details
Main Authors: Zhiwei Zheng, Jingrong Lin, Huide Zhu, Hongfu Cai
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Public Health
Subjects:
cost-effectiveness
KEYNOTE-590 clinical
esophageal squamous cell carcinoma
chemotherapy
pembrolizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2022.893387/full

Internet

https://www.frontiersin.org/articles/10.3389/fpubh.2022.893387/full

Similar Items